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ABSTRACT
Introduction Community pharmacists and their teams 
have remained accessible to the public providing 
essential services despite immense pressures during 
the COVID-19 pandemic. They have successfully 
expanded the influenza vaccination programme and 
are now supporting the delivery of the COVID-19 
vaccination roll- out.
Aim This rapid realist review aims to understand how 
community pharmacy can most effectively deliver 
essential and advanced services, with a focus on 
vaccination, during the pandemic and in the future.
Method An embryonic programme theory was 
generated using four diverse and complementary 
documents along with the expertise of the project 
team. Academic databases, preprint services and grey 
literature were searched and screened for documents 
meeting our inclusion criteria. The data were 
extracted from 103 documents to develop and refine 
a programme theory using a realist logic of analysis. 
Our analysis generated 13 context- mechanism- 
outcome configurations explaining when, why and 
how community pharmacy can support public health 
vaccination campaigns, maintain essential services 
during pandemics and capitalise on opportunities for 
expanded, sustainable public health service roles. 
The views of stakeholders including pharmacy users, 
pharmacists, pharmacy teams and other healthcare 
professionals were sought throughout to refine the 13 
explanatory configurations.
Results The 13 context- mechanism- outcome 
configurations are organised according to decision 
makers, community pharmacy teams and community 
pharmacy users as key actors. Review findings include: 
supporting a clear role for community pharmacies 
in public health; clarifying pharmacists’ legal and 
professional liabilities; involving pharmacy teams 
in service specification design; providing suitable 
guidance, adequate compensation and resources; 
and leveraging accessible, convenient locations of 
community pharmacy.
Discussion Community pharmacy has been able 
to offer key services during the pandemic. Decision 
makers must endorse, articulate and support a clear 
public health role for community pharmacy. We provide 
key recommendations for decision makers to optimise 
such a role during these unprecedented times and in 
the future.
INTRODUCTION
Community pharmacy teams have continued 
to provide essential services during the 
COVID-19 pandemic. They offer accessibility 
and medicines expertise to the public, even 
in challenging times.1–3 However, COVID-19 
creates extra workload demands, such as 
medication dispensing with increases of up to 
33% in prescription numbers.4 To cope with 
this demand community pharmacies have 
increased their opening hours and hired addi-
tional staff.4 Alongside this additional work-
load, they have managed widening coverage 
of the influenza vaccines programme.5
Evidence suggests that community phar-
macy can successfully provide diverse vaccina-
tion services including seasonal and pandemic 
influenza, travel vaccinations and hepatitis B 
for at- risk groups, within the provisions of 
the UK National Health Service (NHS) or 
privately.6 They have successfully provided 
influenza vaccines as an NHS commissioned 
advanced service since 2015.5 One service 
evaluation found that of 485 patients asked, 
99% expressed confidence in their phar-
macist to provide additional vaccinations.7 
Community pharmacy can also support influ-
enza and other vaccinations to combat the 
Strengths and limitations of this study
 ► A diverse group of professional and public stake-
holders validated our findings from the literature.
 ► By using a realist approach, we were able to use a 
broad range of data, including grey literature.
 ► To enable us to develop recommendations in a time-
ly manner the focus of the review was deliberately 
narrow.
 ► The topic could have been informed by other sourc-
es of evidence in particular empirical interviews with 
key stakeholders.
 ► COVID-19 vaccination is a rapidly evolving area and 
this research was based on the best available evi-
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significantly higher COVID-19- related mortality in ethnic 
minorities (excluding White minorities).8 9
The COVID-19 pandemic has stretched NHS capacity 
to safely and efficiently meet public health demands. A 
role for community pharmacy in the national vaccina-
tion service requires an understanding of what phar-
macy teams require to successfully deliver essential and 
advanced services during the pandemic. Such knowledge 
is timely, given the roll- out of COVID-19 vaccines across 
the community.10
Delivering a vaccination programme is a complex 
process and successful delivery is context dependent. A 
realist review helps make sense of complex situations,11 12 
such as how community pharmacy can most effectively 
address the challenges presented by COVID-19. A rapid 
review can generate guidance for decision makers to 
assist with roll- out of COVID-19 vaccinations to commu-
nity pharmacy. This rapid realist review aimed to under-
stand how community pharmacy can most effectively 
deliver essential and advanced services, with a focus on 
vaccination, during the pandemic and in the future.
METHODS
A rapid realist review of academic and other literature, 
supplemented by input from key actors, was undertaken 
to understand how and when community pharmacy 
can effectively support the public health agenda during 
pandemics such as COVID-19. Rapid reviews aim to ensure 
findings are generated and disseminated in response to 
the urgent nature of the situation. To produce this knowl-
edge at pace, we truncated the following review processes:
 ► Programme theory development was undertaken 
within 1 month with input from the project team.
 ► Searching was expedited using broad search terms 
and using a limited number of key data sources.
 ► Data analysis and context- mechanism- outcome config-
uration (CMOC) development focused on where the 
programme theory was considered most important 
during COVID-19.
This realist review was undertaken within 6 months 
(August 2020–January 2021), the protocol was published 
on PROSPERO13 and, where relevant, follows the Realist 
And Meta- narrative Evidence Syntheses: Evolving Stand-
ards (RAMESES) quality and publication standards.14
Stage 1: programme theory development
The project team met virtually to develop an embryonic 
programme theory using four diverse documents from 
an initial search representing a professional journal,15 a 
research journal,16 a policy document (Royal Pharmaceu-
tical Society (RPS))17 and a practical influenza briefing.18 
The team identified the need for (1) enabling guidance 
for community pharmacy (to achieve legitimisation)16; 
(2) practical direction for community pharmacy prac-
tices (to ensure feasibility)15 16; and (3) user assurance 
of appropriate, safe, feasible and timely intervention 
(relative advantage).15 The resultant embryonic theory, 
patterned on a COM- B behavioural model of capability, 
opportunity and motivation leading to behaviour,19 was 
used to inform searching and initial analyses.
Stage 2: literature searching
Searches were conducted (July–August 2020) using 
MEDLINE, EMBASE, CINAHL, Web of Science and 
Scopus for search concepts relating to Pharmacy and 
COVID by AB (see online supplemental appendix 1 
for search strategy). Reference checking and citation 
searching of all included references on Google Scholar 
(using the Publish or Perish tool) were also carried out. 
Given the novelty of the virus, we searched the contents 
of preprint services and the WHO COVID Register. Grey 
literature searches included social media (eg, blogs, facil-
itated Twitter discussion (#Cpharmchat)), community 
pharmacy websites and emails from relevant regulators 
and professional organisations (eg, RPS, Pharmaceutical 
Services Negotiation Committee, General Pharmaceu-
tical Council).
Key inclusion criteria were high or middle- income 
countries, community pharmacy and infectious disease 
management (see online supplemental appendix 2). The 
search covered January 2003–July 2020 to include SARS, a 
comparable condition first identified in 2003. There were 
no restrictions on study designs eligible for inclusion.
Stage 3: data selection and extraction (selection and coding)
Selection and appraisal of documents followed a two- step 
procedure:
1. EY screened the title, abstract and keywords of poten-
tially relevant documents against inclusion criteria. 
A 10% random sample was checked by two research 
team members (AB and MM) for consistency.
2. EY obtained and screened full texts of all documents 
meeting the eligibility criteria.
Relevant data from the included full- text documents 
were coded into NVivo by EY, MM and JB. Some codes 
came from the data (ie, inductive coding); others were 
derived from the programme theory (ie, deductive 
coding) and some were derived using retroduction (ie, 
by interpretation of what might be functioning as mecha-
nisms).20 No assessment was made of the rigour of the data 
within included documents; however, global judgements 
were made of the quality of the explanations provided by 
the CMOCs and programme theory using the criteria of 
consilience, simplicity and analogy.21
Stage 4: data synthesis
The data analysis/synthesis was conducted by EY, MM and 
JB with input from the rest of the project team to develop 
and refine the programme theory using a realist logic 
of analysis. Our analysis generated 13 realist CMOCs, 
explaining when, why and how community pharmacy 
can support public health vaccination campaigns, main-
tain essential services during pandemics and capitalise 
on opportunities for expanded, sustainable public health 
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CMOCs related to care for diverse and vulnerable popu-
lations, including ethnic minorities.
Our realist logic of analysis centred on the following 
questions:
 ► Interpretation of meaning: do the contents coded 
by the team provide data that may be interpreted as 
CMOCs?
 ► Interpretations and judgements about CMOCs: how 
do the CMOCs relate to the programme theory?
 ► Interpretations and judgements about programme 
theory: how do the programme theory and its CMOCs 
correspond with key actor perspectives of reality?
Data to answer our questions were iteratively sought 
across documents. Interpretive cross- case comparison was 
used to identify and explain the ‘success’ of pandemic 
community pharmacy interventions delivered in different 
settings or to different population groups.
Key stakeholders
Key stakeholders, including community pharmacists and 
support staff (including representatives from large and 
smaller chains, sole independent pharmacies and primary 
care), other healthcare professionals and members of the 
public were consulted on four occasions. The meetings 
took place over Microsoft Teams and each lasted about 
1 hour.
Patient and public involvement
Members of the public were drawn from The University 
of Sheffield’s Patient and Public Involvement database 
and contacts of the core project team. Groups numbered 
between 11 and 13 members, with ages ranging from 
22 to 74 years, from diverse locations and ethnicities 
including Black African, Black Caribbean, British Asian, 
British Chinese, White Irish and White British. Collec-
tively, stakeholders provided feedback and advice on their 
real- world experience of working in or using community 
pharmacy.
RESULTS
One hundred and three documents were included in this 
rapid review and were coded to develop and refine our 
CMOCs and programme theory (Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses 
diagram in online supplemental appendix 3). The final 
programme theory is summarised in online supple-
mental appendix 4—from abstract visioning to actual 
patient uptake of the COVID-19 vaccine. Although the 
programme theory is outlined in a linear fashion, steps 
within it are not necessarily linear and may occur simul-
taneously. The CMOCs are organised according to key 
actors, or individuals and groups with a vested interest 
in community pharmacy delivery of a COVID-19 vacci-
nation programme. ‘Actor’ derives from sociology and is 
synonymous with ‘stakeholder’; we privileged this term 
to differentiate programme theory/CMOC organisation 
from project stakeholder participants.22 Table 1 briefly 
describes the three actor groups with their respective 
CMOCs and corresponding steps in online supplemental 
appendix 4. Tables 2–4 show the final 13 CMOCs.
The following sections summarise the CMOCs related 
to each of the three actor groups. Illustrative examples 
of the supporting evidence from review documents are 
presented (tables 2–4).
Decision makers
Decision maker and public endorsement (CMOC 1) are 
essential first steps in enlisting community pharmacy for 
COVID-19 vaccination programmes. Regulators must 
ensure pharmacists have the legal scope to do so (CMOC 
Table 1 Programme theory actors with corresponding CMOCs and steps
Programme theory actors Description CMOCs* Steps in programme theory†





Community pharmacists are healthcare 
professionals registered by the General 
Pharmaceutical Council and supported by teams 
made up of counter assistants, dispensers 
and registered technicians. They work in high 
street locations, in local communities and in 
supermarkets. Employers range from large 
chains to small individually owned community 
pharmacies.
5–9 5–7 and 9–11
Pharmacy users Members of the public who use any community 
pharmacy services including prescription 




†See online supplemental appendix 4.
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2), with community pharmacy input during the develop-
ment of policies and protocols (CMOC 3), so that final 
service specifications are flexible and doable within local 
settings (CMOC 4).
In England community pharmacies have govern-
ment contracts and partnerships to deliver vaccina-
tions and other essential services during emergencies, 
including the COVID-19 pandemic.23–25 Pharmacies 
in the USA and Canada have also been identified as 
having a substantive role in vaccine administration 
(CMOC 1).23 26 The idea of harnessing UK community 
pharmacy capacity enjoys widespread public support 
(CMOC 2).27 However, appropriate service delivery 
is hampered by unfeasible operational conditions 
(CMOC 3)1; for example, medication deliveries are 
funded by the UK government for ‘vulnerable people’, 
but this category of service users is defined narrowly 
by the government and misunderstood by the public, 
creating unrealistic expectations of community phar-
macy and generating additional work.1
Table 2 Decision makers (CMOCs 1–4)
CMOC 1— support a 
public health role23–27 
62 66–69
When the government, pharmacy regulators, professional bodies and the public endorse 
and support a clear role for community pharmacy in public health services (C), community 
pharmacists will be more likely to adopt vaccination services (O) because they see it as their 
professional role and duty (M).
‘Distribution and administration of the COVID-19 vaccination programme will require concerted 
action across the NHS. With unique insight and expertise in medicines and the delivery of vaccination 
programmes, pharmacists have a clear role in contributing to the success of this programme.’ (Great 
Britain)66
‘55% of the public have visited a pharmacy during the COVID-19 crisis…89% of people believe 
pharmacies are playing an essential role in the COVID-19 crisis.’ (UK National Pharmacy Association)27
‘Pharmacists…have been called on to coordinate the administration of COVID-19 tests…providing 
ongoing COVID-19 surveillance to communities by allowing walk- in testing at community pharmacies…
[This] might be more sustainable and convenient than the large- scale public screening being done as of 
the summer of 2020.’ (USA)23
‘Given the past success of community pharmacists with increasing annual seasonal influenza uptake 
and their accessibility, pharmacists will need to be central in administering COVID-19 vaccines in order 
to achieve rapid population- wide coverage.’ (Canada)26
CMOC 2—clarify 
legal and professional 
liabilities24 28 66 70–76
When pharmacy regulators and the NHS clarify community pharmacists’ legal and professional 
liabilities arising from the administration of a novel and potentially unlicensed COVID-19 vaccine 
(C), community pharmacists are more willing to give the vaccination (O) because they feel 
reassured regarding liability (M).
‘The role of pharmacists in the COVID-19 vaccination programme must be made clear to the pharmacy 
profession itself. Professional and representative pharmacy bodies have an important role to play 
in providing the right level of information to the profession to support their roles in the vaccination 
programme.’ (Great Britain)66
‘Indemnity insurance for individual healthcare professionals needs to be amended to cover this activity 
and be state- funded. There also needs to be clear communication to healthcare professionals, so they 
clearly understand that they are covered and under which circumstances this applies.’ (Great Britain)77
CMOC 3—Codevelop 
feasible service 
specifications1 28 37 54 
78–82
When COVID-19 vaccination policy and service specifications have been developed with input 
from diverse community pharmacists and staff tasked with administering and supporting the 
administration of the vaccine (C), community pharmacies are more likely to deliver the service 
(O) because they believe the service specification is feasible (M).
‘Pharmacists ideally want input into future policy changes before they are finalized, so that these can 
reflect capacity and preparedness on the ground and be publicized accurately.’ (Great Britain)1
CMOC 4—issue clear, 
relevant and timely 
guidance23 24 28 31 35 37 
46 67 71 83–92
When government, pharmacy regulators and professional bodies provide consistent, clear, 
relevant and timely guidance for the delivery of the COVID-19 vaccines (C), community 
pharmacies are more likely to deliver the service (O), because the guidance is helpful and 
simplifies implementation (M).
’… it is good to see that NHSE/I have provided the information we have been waiting for to review the 
resources we have nationwide and decide how we can bring them to bear to help the NHS defeat this 
virus.’ (Great Britain)28



































































































































































Table 3 Community pharmacists and team (CMOCs 5–9)
CMOC 5—receive 
adequate compensation 
and resources1 30 32 40 45 
93–103
When community pharmacies receive adequate compensation and resource support for COVID-19 vaccines (C), they are more likely to 
deliver the service (O), because they feel recognised for their service contributions (M).
‘Pharmacists…have been incredible in supporting patients throughout COVID-19 and rightly deserve recognition for the work they do. We know 
that teams were already under pressure and that colleagues in community pharmacy are feeling added financial strain.’ (Great Britain).30
‘In the community, mitigating the impact of COVID-19 has…focused largely on general practitioners (GPs). This is unsurprising to those in the 
pharmacy profession who have long considered policy makers to overlook them.’ (Great Britain)1
CMOC 6—sustain 
capacity and facility 
to adapt essential 
services16 17 32–34 44 69 71 96 
97 104–115
When a community pharmacy has the capacity and permission to manage and adapt existing essential services during COVID-19 (C), 
they are more likely to effectively deliver and sustain these services (O) because it is feasible for them to do so (M).
‘Virtual and telephone consultations have become commonplace, particularly to vulnerable patients. Pharmacists have implemented systems to 
dispense medications in advance of need to minimise wait times and duplicate visits. In case- by- case examples…there has been anticipatory 
management of medication- related needs.’ (Ireland)115
‘Pharmacists who had comfort and confidence in managing electronic communication reported feeling greater control over workflow and the 
ability to triage and queue patients more effectively based on priority and need.’ (Canada)46
CMOC 7—inform users 
of essential service 
availability/continuity16 24 
25 33–35 45 46 62 97 109 115–124
When community pharmacies have processes in place to inform pharmacy users about the availability of essential services (C), 
pharmacy users are less likely to become anxious (O), because they feel reassured about access to what they need (M).
‘Access to medications is a main concern expressed by our patients… The CDC and SAMHSA offer guidance on ways to reduce stress and 
anxiety in this time of uncertainty.’118
‘As a result of the power dynamics at play, it is ultimately up to pharmacists to be able to reassure patients and provide care, all while taking into 
account their mental health. Currently, guidelines regarding patient interaction during a pandemic are needed.’35
‘In addition, there is ongoing work in liaison with pharmacists, general practitioners, and state and territory authorities to enable therapeutic 
substitution by pharmacists in the event of a shortage. This will allow community pharmacists to substitute dose strength or form without prior 
approval from the prescriber, if a prescribed medicine is not available at the time of dispensing. These measures highlight the important role 
pharmacists can play in enabling and maintaining access to medicines for people in need throughout the COVID-19 outbreak.’ (Australia)109
‘Access to medications is a main concern expressed by our patients… The CDC and SAMHSA offer guidance on ways to reduce stress and 
anxiety in this time of uncertainty.’ (USA)118
Continued























































CMOC 8—protect the 
health and safety of 
staff24 34 35 55 66 97 103 
125–130
When community pharmacies have the means to protect the health of pharmacists and staff (C), they are more likely to deliver essential 
services and COVID-19 vaccination services (O), because they feel safe to do so (M).
‘…Given high levels of public anxiety and uncertainty regarding the integrity of the drug supply chain in Canada, many participants reported 
difficult, sometimes frightening, interactions with members of the public and their desire for dedicated security to provide support and conflict 
management.’ (Canada)24
‘An additional burden Asian pharmacists face, on top of pharmacist harassment, is the rise of anti- Asian racism that has come about due to 
COVID-19. Verbal and even physical abuse has been reported to happen in various countries, such as the UK, France, and the USA, to those of 
Chinese descent…’ (UK, France, USA)35
‘The survey found that although more than a third (37%) of pharmacists said they felt unsafe at some point working during the pandemic, 
concerns over PPE have eased. This is due, in part, to the supply problems being eased and community pharmacists being finally allowed to 
order from the national online PPE portal in an emergency, after calls for access from the RPS.’ (Great Britain)103
CMOC 9—enhance 
collaboration across 
services, including IT18 26 
33 40 41 82 88 89 104 109 131–135
When systems needed for COVID-19 vaccination, including IT and remuneration, support collaboration by various service providers (eg, 
general practitioner surgeries and community pharmacies: (C)), a coordinated response is more likely (O), because reduced effort is 
needed from everyone (M).
‘Planning and delivery should be undertaken across a consistent, pre- agreed footprint. It may be more efficient and cost effective to provide 
immunisation across a number of providers, pooling resources and sites to deliver the best service possible, and working in coordination with 
other local stakeholders such as directors of public health and local government.’ (Great Britain)82
‘For many community pharmacists, a lack of connected IT is a huge problem. Kieran Eason, who runs an independent pharmacy in Tamworth, 
Staffordshire, says lack of intra- operability makes it more difficult to do relatively simple things, like sending prescription requests to GPs. 
“Pharmacy IT is just a complete disaster,” he says, suggesting the COVID-19 crisis has highlighted flaws, such as the number of different systems 
pharmacists use.’ (Great Britain)40
CDC, Centers for Disease Control and Prevention; CMOC, context- mechanism- outcome configuration; IT, information technology; PPE, personal protective equipment; RPS, Royal 
Pharmaceutical Society; SAMHSA, Substance Abuse and Mental Health Services Administration.
Table 3 Continued
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In contrast, when clear options for community phar-
macy involvement in COVID-19 vaccination programmes 
were issued through the NHS (CMOC 4), the chief exec-
utive of the Association of Independent Multiple Pharma-
cies commented positively on members’ engagement in 
delivering vaccines.28
Community pharmacists and team
Community pharmacies have had to manage ongoing 
essential services, in addition to supporting COVID-19 vacci-
nation delivery during the pandemic (CMOC 6), including 
delivery of necessary medications (CMOC 7). Given fears 
and anxieties related to COVID-19 and changes to service 
delivery, community pharmacies have had to deal with inap-
propriate behaviours from the public, including emotional 
abuse and threats of physical abuse (CMOC 8). As an inte-
gral public health service, community pharmacy capacity to 
meet NHS needs will be enhanced through use of informa-
tion technology (IT) and collaboration with other service 
providers (CMOC 9).
Although attention is focused on a COVID-19 vaccine, 
community pharmacies offer diverse essential services. 
In the UK and other high- income countries, community 
pharmacy services also provide advanced services such 
as vaccinations.29 Pharmacists consider it a professional 
Table 4 Pharmacy users (CMOCs 10–13)
CMOC 10—trust the 
pharmacist as reliable 
information source25 61 85 136–138
When pharmacy users receive information about the COVID-19 vaccine from their community 
pharmacy (C), they are more likely to get the vaccine (O), because they trust community 
pharmacy as a source of reliable, accurate information (M).
‘When patients were educated about influenza, herpes zoster, and pneumococcal vaccines as a result 
of a pharmacist- driven intervention in community pharmacies, they were influenced to receive the 
vaccination.’ (USA)136
‘Being able to address the public enquiries with accurate up-to- date information about the local 
situation and the overall infection progress is the key to build trustful relationship with them at troubled 
times.’ (Macau)25
CMOC 11—trust the 
pharmacist to deliver 
responsive services7 18 26 27 30 31 
35 42 43 54 71 74 86 96 108 109 139–149
When community pharmacies are trusted to make necessary service adaptations to ensure 
services are flexible, convenient and accessible (C), COVID-19 vaccine uptake is likely to be 
higher among pharmacy users (O) because the service is responsive to local needs (M).
‘Pharmacists have always been the most accessible health care provider; this is especially true in 
the era of COVID-19….While other professionals have closed their doors to patients, community 
pharmacies remained open to the public despite stricter lockdown restrictions. As highly trusted 
healthcare clinicians, community pharmacists play a vital role in closing the gaps that are exacerbated 
by the additional strain on the system and reduced access to healthcare providers.’ (Canada)35
‘Pharmacy flu vaccination services complement those provided by general practitioners to help 
improve overall coverage and vaccination rates for patients in at- risk groups. These services are highly 
accessed by patients from all socio demographic areas, and seem to be particularly attractive to 
carers, frontline healthcare workers, and those of working age.’ (Great Britain)149
CMOC 12—access culturally 
sensitive services33 67 104 115 150
When community pharmacies leverage their community location and community–staff 
relationships (C), vulnerable populations, such as ethnic minorities, are more likely to use 
their services, including COVID-19 vaccination services (O), because they trust their local 
community pharmacies to provide culturally sensitive service (M).
‘Research continues to highlight that patients who are medically under- served have poorer inequitable 
access to health care due to them experiencing greater physical barriers to accessibility, encountering 
poorer patient- professional communication and are significantly disadvantaged where a service is not 
tailored to their unique needs or preferences.’ (Great Britain)151
‘I think over the years what’s happened is nationally it’s almost like everything has to be the same, 
which then doesn’t work because it doesn’t accommodate all the little variations…So we need to go 
back and in each individual pharmacy, gear it towards the population that it is meant to be meeting the 
needs of.’ (Pharmacist caring for ethnic minority community—Great Britain)151
CMOC 13—receive private and 
confidential services7 43 45 83 
152–154
When community pharmacies make provisions for privacy (C), pharmacy users are more likely 
to use their services (O), because they are reassured about confidentiality (M).
‘If there was something not right…the first thing I would do is make an appointment with a doctor. I 
wouldn’t do and talk to somebody over a pharmacy counter.’ (Great Britain)45
‘Privacy, confidentiality and dignity are all vital elements of a trusting relationship between healthcare 
professionals and their patients…. In terms of privacy, the quality was perceived by the participants to 
include a confidential room that enabled private consultations.’ (Great Britain)7
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responsibility to provide essential services during the 
pandemic, despite clear financial risks to themselves.30
Despite pharmacists’ professional and moral obliga-
tions to provide essential services, ongoing persistent 
‘under- recognition’ can jeopardise their ability to 
contribute to COVID-19 vaccinations (CMOC 5) as well 
as maintain a usual service. Under- recognition has been 
an issue in previous UK vaccination campaigns; respon-
dents to a survey of Welsh community pharmacists after 
the 2016 influenza season described providing a ‘mop up’ 
service for general practitioners (GPs).31 32
Multiple required community pharmacy service adap-
tations have been reported by the UK Pharmaceutical 
Journal, including change- over in retail space to medi-
cation preparation and dispensing, and call- in shop-
ping services for other retail items (CMOC 6). Service 
adaptations have been affected by hours of opera-
tion, available staff and cancellations of contracted 
services, such as blood pressure testing and smoking 
cessation support—all with financial implications for 
pharmacists.33
Before COVID-19, community pharmacies globally 
were offering ‘valued- added services’ (VAS) such as 
drive- thru services, online ordering and communications 
services (eg, prescription reminders) to stay competitive. 
Many VAS have helped pharmacies adapt more quickly to 
pandemic restrictions.34
During the pandemic, ensuring access to needed medi-
cations has been a critical pharmacy service, to allay 
public concerns (CMOC 7).16 Potential and actual disrup-
tions in expected services and needed supplies (eg, medi-
cations) have resulted in tensions, threats and verbal/
physical abuse by the public to community pharmacists 
(CMOC 8).33 35 36 Safety policies, protocols and safety- 
related supplies (eg, personal protective equipment 
(PPE)) must be in place to ensure community pharmacy 
teams’ safety.33
The UK COVID-19 vaccination campaign borrows 
heavily from previous, successful collaborative influ-
enza vaccination programmes using community 
pharmacy and GPs (CMOC 9).37 Pooling resources 
improves service delivery.38 For example, the UK Phar-
maceutical Journal reported how a greater collabo-
rative approach has resulted in successful influenza 
vaccination of home care staff and domiciliary workers 
during the pandemic.38
The pandemic has clearly demonstrated the impor-
tance of interoperable, connected IT systems across 
services.39 Getting access to reliable information 
is important for tracking supplies and deliveries 
related to the COVID-19 vaccination programme.40 A 
pandemic silver lining is raised awareness of IT func-
tions for enhanced delivery of essential services (eg, 
medication planning, prescribing and dispensing 
between pharmacies and GPs) and advanced services, 
including vaccinations.40
Pharmacy users
Pharmacy users trust community pharmacies as a reli-
able source of information (CMOC 10) about vaccines, 
and pharmacies’ local accessibility and convenience 
increases the likelihood of users obtaining COVID-19 
vaccines through them (CMOC 11). Community phar-
macy relationships with vulnerable populations in 
their local settings may enhance uptake of the vaccine 
by these groups (CMOC 12). Provision for privacy is an 
important user consideration. Pharmacy users expect 
private consultations to preserve their confidentiality 
(CMOC 13).
Public trust in community pharmacists is high—
similar to doctors and nurses.28 Trust between pharma-
cists and users can be leveraged to overcome scepticism 
about the COVID-19 vaccine. Providing reliable infor-
mation about the disease and the vaccine, as phar-
macies have done with other infections, can enhance 
public uptake of the COVID-19 vaccine.41 In the USA, 
90% of the US population lives within 5 miles of a 
community pharmacy. Given their convenience and 
accessibility, consumers have visited their community 
pharmacists 12 times more frequently than their GPs.21 
A UK study found that consumers who were eligible for 
a free influenza vaccine through their GPs were willing 
to pay for pharmacy service because of convenience 
and ease of access.42 Established, trusting relationships 
are especially important for providing culturally sensi-
tive services to marginalised and vulnerable commu-
nities.43 Community pharmacists, often members of 
local communities, are specially positioned to under-
stand the culturally contextual factors that impact 
their pharmacy users.44 Trusting relationships are 
founded on privacy, confidentiality and dignity, and 
COVID-19, public health protocols and limited space 
must be considered—in order to maintain vital trust 
among pharmacy users.45
DISCUSSION
This realist review sought to understand how community 
pharmacy can contribute to the public health agenda 
during the COVID-19 pandemic, particularly continua-
tion of essential services and engagement in vaccination 
services.29 As the COVID-19 vaccination service continues 
to evolve, our recommendations for decision makers 
highlight opportunities for community pharmacy to 
promote safe, efficient and effective service delivery.
Summary of key findings
To optimise community pharmacy service during the 
pandemic, decision makers must endorse and articu-
late a clear role for these healthcare professionals. The 
public already endorses advanced roles for community 
pharmacy (eg, vaccinations, minor ailment scheme), 
but public awareness depends on what decision makers 
do and say. Practical decision maker measures include 
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staff and PPE (particularly for a sustainable long- term 
service); legal (including indemnity), regulatory coverage 
for advanced roles; and clear and consistent guidance for 
vaccination preparation and for adaptation of essential 
services. When given the opportunity, the permissions 
and resources to do so, community pharmacies have 
been able to adapt quickly to continue essential services 
and whenever possible, to offer critical advanced services. 
Historically, community pharmacies have significantly 
increased vaccination uptake (eg, influenza vaccinations) 
given their accessibility and convenience and capacity 
to adapt to local needs for the general population and 
marginalised groups.
Compare to other similar or related studies discussing 
important differences in results
At the time of this realist review, there were no similar 
reviews on community pharmacy roles with respect 
to COVID-19 vaccinations. COVID-19 represents an 
unprecedented situation with limited direct evidence 
to guide decision- making. However, realist approaches 
engage with a wider evidence base, including research 
on past pandemics (eg, SARS),46–48 mass vaccination 
campaigns (eg, influenza)49 and community pharmacies’ 
capacity pre- COVID-19 to deliver essential and advanced 
services.19 50 51 Key factors previously include a lack of 
leadership, a lack of guidance and an increasing reliance 
on professional judgement and experience.46 Research 
from the UK and other economically developed countries 
supports the 13 CMOCs and decision maker recommen-
dations in this review (see tables 2–5). However, limita-
tions continue to surround the direct policy relevance of 
much of the community pharmacy evidence base.52
Strengths and limitations
The realist approach uses diverse data, including grey 
literature. This feature is especially important given a 
novel and rapidly evolving topic area, such as COVID-19. 
Multiple researchers with subject matter expertise partic-
ipated in screening the literature and extracting and 
coding data, which maximised opportunities to discuss 
and debate the plausibility of the inferences made. The 
CMOCs were developed and refined through regular 
discussions within a team with varied academic and clin-
ical backgrounds. Professional and public stakeholder 
consultation further refined the CMOCs.
All rapid reviews operationalise coverage versus expedi-
ency. Other sources of evidence could have informed the 
review; however, potential gaps were mitigated by stake-
holder engagement and expertise within the team. The 
evidence supporting the CMOCs was based on available 
time for document review, and during the review period, 
research, directives and policy related to COVID-19 vacci-
nation rapidly evolved. The programme theory and its 
CMOCs, however, are expressed in such a way that they 
can be further confirmed, refuted or refined in the future 
using additional data.
For this rapid review, given our short timeline of 6 months, 
we initially decided to focus on community pharmacy roles 
and pandemic response in middle to high- income coun-
tries. While we identified data from higher income coun-
tries such as Canada, USA, Australia and France, there was 
very little published from middle- income countries. As 
such, it is likely that our findings and recommendations 
are most applicable to high- income countries, although the 
lessons learnt from high- income countries can serve as an 
initial reference point for best practice for other countries.
Table 5 Recommendations for decision makers to increase community pharmacy engagement in pandemic response 
(for further details check: https://publications.aston.ac.uk/id/eprint/42310/1/Guidance_for_Policy_Makers_on_the_role_of_
Community_Pharmacy_in_COVID.pdf)
Recommendations Derived from CMOC
Articulate a clear public health agenda role for community pharmacy (eg, COVID-19 testing and 
vaccination).
1
Ensure pharmacy regulations for advanced roles, such as novel vaccine administration, are in place to 
legally protect community pharmacists and their teams.
2
Involve local community pharmacies in policy and service specification development. 3
Provide timely guidance with sufficient details for community pharmacies to quickly adapt to local 
needs.
4
Provide adequate funding and reimbursement for community pharmacy services to deliver COVID-19 
vaccines.
5
Equip community pharmacies with the necessary permissions to manage and adapt essential 
services.
6
Ensure community pharmacies have the means to adequately protect the health of themselves, their 
staff and pharmacy users.
8
Facilitate collaboration and coordination of COVID-19 vaccination services across providers (eg, GPs, 
community pharmacies) and systems (eg, IT).
9
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Our recommendations can be viewed as ‘how tos’ for 
other countries to consider within their own cultural and 
healthcare environments. A number of European and 
North American countries have introduced legislative 
changes to extend the role of community pharmacy and 
thus reduce pressure on other parts of their healthcare 
systems.51 53 Our findings can be used by community phar-
macy and decision makers, from countries other than the 
UK, when mapping out similar services particularly in the 
context of changes in the legislation.
Meaning of the study: possible explanations and implications 
for decision makers
Although there are multiple actors involved in pandemic 
response, for brevity, recommendations (table 5) are 
directed towards decision makers who possess the formal 
authority to implement the recommendations.
As the CMOCs were refined, ‘tensions’ were uncov-
ered with implications for decision makers, particularly: 
community pharmacists as healthcare professionals 
versus retailers51 54–56; community pharmacies’ capacity 
to remain financially viable while managing essential 
and advanced services19 57 58; and pharmacists’ capacity 
to provide offsite services while maintaining physical 
premises.59 These tensions stem from lack of awareness of 
community pharmacists as healthcare professionals.
Along the continuum of healthcare from commu-
nity to hospital, community pharmacy is often the first 
point of contact for the public. Community pharmacies 
contribute to primary care services through essential 
services (eg, medication dispensing) and expanded roles 
(eg, vaccinations),29 56 often decreasing workload pres-
sures on other providers, such as GPs.60 Public surveys 
demonstrate high levels of satisfaction with community 
pharmacy services, and vaccination uptake is increased 
when pharmacies deliver these services.58 Nevertheless, 
lack of public and decision maker awareness of commu-
nity pharmacy primary care roles has slowed uptake 
and integration of these services.61 A recent UK public 
survey found that community pharmacies are seen as ‘a 
medicine supply shop by 48.3% of people, as a place to 
purchase medicines by 22%, and a place to purchase non- 
medicinal products by 17.7%’.62
In Ireland and Canada, community pharmacies are 
an integral part of national vaccination campaigns.58 In 
both instances, community pharmacists participate in 
vaccination planning, pharmacy regulators provide clear 
guidance on vaccination management and vaccinations 
are equitably refunded through public health systems. 
The removal of barriers, such as economic pressures on 
pharmacies, has resulted in impressive national vaccine 
uptake, even in large countries, such as Canada.58 Glob-
ally, there is an emerging trend for governments, health 
insurance companies and consumers to remunerate 
community pharmacies for services that contribute to 
improved health outcomes.59
Community pharmacies tend to be defined as premises 
where medications are dispensed, which compounds the 
confusion (by the public and decision makers) of profes-
sional primary care services versus retailers.59 Instead, 
pharmacies should be defined with respect to actions or 
services that require specialised health knowledge to opti-
mise health outcomes. For example, a retail approach 
to over- the- counter (OTC) medications is to permit 
consumers to make their own choices, similar to super-
market choices. Pharmacy input into OTC purchases 
could potentially decrease adverse medication interac-
tions or unnecessary allergic reactions.56 The ‘value- add’ 
of community pharmacies, evidence- informed engage-
ment with consumers, can decrease morbidity and 
mortality outcomes and increase medication regimen 
adherence.59 63
Although community pharmacists can provide profes-
sional services off premises (eg, immunisations in 
community and religious centres), they need to maintain 
their physical premises and staff for financial reasons. In 
addition, pharmacy users seek out community pharmacy 
services due to their accessibility and convenience, and 
without a physical space to engage regularly with phar-
macy users, trust building between pharmacists and users 
is compromised.64
As evidenced by public media, many countries, 
including the UK, are declaring service specifications 
for COVID-19 vaccinations. Community pharmacists can 
potentially provide vaccination services in two locations.65 
They can collaborate with GPs in Primary Care Networks 
(PCN) to support PCN vaccination sites. Alternatively, 
they can provide a COVID-19 vaccination service from 
their premises if they meet service specifications. The 
described tensions create difficult choices for pharma-
cists that can be ameliorated through the decision maker 
recommendations in table 5.
Unanswered questions and future research
A future realist evaluation involving primary data collec-
tion from key actors will inform refinement of the 
programme theory, CMOCs and decision maker recom-
mendations. This empirical research will address the 
tensions identified above. Future research will also address 
issues identified through the stakeholder groups, such as 
vaccination hesitancy, outside the scope of this review. 
While this work touched on unique issues for marginal-
ised populations including ethnic minorities, those of 
lower socioeconomic status and those with disabilities, 
further exploration is needed.
We had initially focused the review on community 
pharmacy roles and pandemic response in middle to 
high- income countries, but found limited data in middle- 
income countries. The findings are thus more likely to 
be applicable to high- income countries but may serve 
to inform practice elsewhere. Empirical research using, 
for example, a realist evaluation approach should be 
conducted to extend our findings on the role of commu-
nity pharmacy in COVID-19 vaccination programmes to 
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CONCLUSION
The COVID-19 pandemic is a worldwide health emer-
gency. Vaccination is key to combating the pandemic. 
The role of community pharmacy may be both short term 
and long term; with a potential need for regular annual 
vaccines. This rapid realist review offers recommenda-
tions for decision makers to enable community pharmacy 
to play a key role, both during these unprecedented times 
and into the future.
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Appendix 1 - OVID MEDLINE – Search Strategy 
 
1. exp Coronavirus/ or exp Coronavirus Infections/ or (coronavirus* or "2019‐nCoV" or "2019 ncov" 
or nCov or "Covid 19" or Covid19 or "SARS CoV 2" or novel coronavirus or novel corona virus or 
covid* or "coronavirus 2" or coronavirus infection* or coronavirus disease or corona virus disease or 
new coronavirus or new corona virus or new coronaviruses or novel coronaviruses or wuhan).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, floating sub‐
heading word, keyword heading word, organism supplementary concept word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier, 
synonyms] 
2. (Community pharmacy or community pharmacies or community pharmacist or community 
pharmacists or retail pharmacy or retail pharmacist or retail pharmacists or dispensing chemist or 
dispensing chemists or (((Pharmacist or pharmacy) and (community or primary care)) or dispensary 
or apothecary or druggist)).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, floating sub‐heading word, keyword heading word, organism supplementary concept 
word, protocol supplementary concept word, rare disease supplementary concept word, unique 
identifier, synonyms] 
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